Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30585989 | 0.98 | NPC1 (0.54) | NPC1RAB9APKMGAAGRM1 | |
| Hydrochloric Acid SCHEMBL21640960 | 0.98 | NPC1 (0.54) | NPC1RAB9APKMGAAGRM1 | |
| Trifluoroacetic Acid SCHEMBL4920824 | 0.90 | NPC1 (0.50) | NPC1RAB9APKMGAAGRM1 | |
| SCHEMBL16686677 | 0.88 | RAB9A (0.53) | NPC1RAB9APKMGAAGRM1 | |
| SCHEMBL3671286 | 0.86 | HPGD (0.65) | NPC1RAB9APKMGAAGRM1 | |
| SCHEMBL30355896 | 0.86 | HPGD (0.65) | NPC1RAB9APKMGAAGRM1 | |
| SCHEMBL2475102 | 0.86 | RAB9A (0.56) | NPC1RAB9APKMGAAGRM1 | |
| Hydrochloric Acid SCHEMBL27396506 | 0.84 | RAB9A (0.55) | NPC1RAB9APKMGAAGRM1 | |
| SCHEMBL1515418 | 0.83 | RAB9A (0.60) | NPC1RAB9APKMGAAGRM1 | |
| SCHEMBL27488421 | 0.83 | RAB9A (0.63) | NPC1RAB9APKMGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | NPC1 1122/4885RAB9A 2080/4885PKM 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.